Literature DB >> 16828789

A novel ELISA for mouse activated protein C in plasma.

José A Fernández1, Steven R Lentz, Denis M Dwyre, John H Griffin.   

Abstract

The Protein C pathway plays a crucial role in the regulation of thrombosis and inflammation. One of the tools that researchers presently use to elucidate mechanisms of action of activated protein C (APC) is the use of transgenic or gene deletion murine models. To correlate observations in these murine models with the APC levels, there is a need for a sensitive and specific assay for circulating murine APC in plasma. We developed an immunological assay to measure the physiological and pharmacologic levels of circulating murine APC. The sandwich ELISA uses an anti-murine anti-protein C antibody capture antibody and human protein C inhibitor (PCI) as a detection reagent, taking advantage of the facts that the mouse lacks plasma PCI and that human PCI forms a 1/1 stable complex with mouse APC. The amount of complex APC:PCI is detected with an anti-human PCI monoclonal antibody. The assay shows improved sensitivity versus enzyme immunocapture assays commonly used to detect human APC and considerably reduces the processing time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828789     DOI: 10.1016/j.jim.2006.05.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis.

Authors:  Thomas J Raife; Denis M Dwyre; Jeff W Stevens; Rochelle A Erger; Lorie Leo; Katina M Wilson; Jose A Fernández; Jennifer Wilder; Hyung-Suk Kim; John H Griffin; Nobuyo Maeda; Steven R Lentz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

2.  Generation and phenotypic analysis of protein S-deficient mice.

Authors:  François Saller; Anne C Brisset; Svetlana N Tchaikovski; Monica Azevedo; Roman Chrast; José A Fernández; Marc Schapira; Tilman M Hackeng; John H Griffin; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2009-06-30       Impact factor: 22.113

3.  Quantitative analysis of thrombomodulin-mediated conversion of protein C to APC: translation from in vitro to in vivo.

Authors:  Ronald Carnemolla; Kruti Rajan Patel; Sergei Zaitsev; Douglas B Cines; Charles T Esmon; Vladimir R Muzykantov
Journal:  J Immunol Methods       Date:  2012-06-27       Impact factor: 2.303

4.  Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Authors:  Zhihui Zhong; Hristelina Ilieva; Lee Hallagan; Robert Bell; Itender Singh; Nicole Paquette; Meenakshisundaram Thiyagarajan; Rashid Deane; Jose A Fernandez; Steven Lane; Anna B Zlokovic; Todd Liu; John H Griffin; Nienwen Chow; Francis J Castellino; Konstantin Stojanovic; Don W Cleveland; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

5.  Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier.

Authors:  Rashid Deane; Barbra LaRue; Abhay P Sagare; Francis J Castellino; Zhihui Zhong; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2008-10-08       Impact factor: 6.200

6.  Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1.

Authors:  Meenakshisundaram Thiyagarajan; José A Fernández; Steven M Lane; John H Griffin; Berislav V Zlokovic
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

7.  Is protein C inhibitor antithrombotic and protective in pulmonary hypertension?

Authors:  L M Beaulieu; F C Church
Journal:  J Thromb Haemost       Date:  2006-09-15       Impact factor: 16.036

8.  miRNA-1283 Regulates the PERK/ATF4 Pathway in Vascular Injury by Targeting ATF4.

Authors:  Ling He; Jing Yuan; Qingyun Xu; Ruixue Chen; Liguo Chen; Meixia Fang
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.